Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma (METEOR)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Exelixis Identifier:
First received: May 21, 2013
Last updated: July 14, 2016
Last verified: July 2016